Your search for Warfarin returned 273 results

Your search for Warfarin returned 273 results

Sort Results:

Relevant Recent
Drug Monograph

COUMADIN

Warfarin sodium 1mg, 2mg, 2½mg, 3mg, 4mg, 5mg, 6mg, 7½mg, 10mg (dye-free); scored tabs.
Drug News

Fruits Most Likely to Cause Warfarin Interactions

Purpose: The aim of this review is to discuss possible interactions that may occur between warfarin and fruit products. Methods: A literature search was conducted using the search terms: “warfarin (Coumadin®) and fruit interactions, warfarin and fruit, warfarin and fruit juice, case reports and clinical trials”.
Drug News

Warfarin Linked to Lower Cardiac Risk in CKD With A-Fib

For patients with established cardiovascular disease and atrial fibrillation, warfarin treatment correlates with a lower risk of a composite of death, myocardial infarction (MI), and ischemic stroke, with no increased risk of bleeding.
Drugs in the Pipeline

Dabigatran Comparable to Warfarin in DVT/PE Trial

Boehringer Ingelheim announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
Clinical Charts

Anticoagulant Dosing Conversions

Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
News

Resuming Warfarin After GI Bleed Cuts Mortality

In the 90 days following a gastrointestinal tract bleeding (GIB) event, patients who do not resume warfarin therapy experience an increased rate of thrombosis and death.
News

Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With VTE

Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…